Cranshire buys 9 million shares of Cell Therapeutics for 7.1% stake

By Lisa Kerner

Charlotte, N.C., April 23 - Cell Therapeutics, Inc. investors led by Cranshire Capital, LP bought a net 9,090,572 shares of the company's stock through a series of buy and sell transactions between March 26 and April 23, according to a schedule 13D filed on Thursday with the Securities and Exchange Commission.

The shares were priced from $0.268 to $0.676, the filing said.

Cranshire beneficially owns 33,504,923 shares or 7.1% of the Seattle biopharmaceutical company's outstanding stock.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.